EP1833817B1 - Synthesis of ccr5 receptor antagonists - Google Patents

Synthesis of ccr5 receptor antagonists Download PDF

Info

Publication number
EP1833817B1
EP1833817B1 EP06717461A EP06717461A EP1833817B1 EP 1833817 B1 EP1833817 B1 EP 1833817B1 EP 06717461 A EP06717461 A EP 06717461A EP 06717461 A EP06717461 A EP 06717461A EP 1833817 B1 EP1833817 B1 EP 1833817B1
Authority
EP
European Patent Office
Prior art keywords
compound
formula
group
carbamate
reacting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP06717461A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1833817A2 (en
Inventor
Wenxue Wu
Bosco D'sa
Feng Liang
Loc Thanh Tran
William Leong
Vilas Dahanukar
Ilia A. Zavialov
Cecilia Proietti
Shannon Zhao
Hong-Chang Lee
Yi Liu
Hoa N. Nguyen
Xiongwei Shih
Man Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of EP1833817A2 publication Critical patent/EP1833817A2/en
Application granted granted Critical
Publication of EP1833817B1 publication Critical patent/EP1833817B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Definitions

  • This application concerns the synthesis of the CCR5 receptor antagonist 4-[4-[(R)-[1-[cyclopropylsulfonyl)-4-piperidinyl](3-fluorophenyl)methyl]-3(S)-methyl-1-piperazinyl]-1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]-4-methylpiperidine.
  • the compound of Formula I is an antagonist of the CCR5 receptor and is useful for the treatment of AIDS and related HIV infections.
  • CCR5 receptors have also been reported to mediate cell transfer in inflammatory diseases such as arthritis, rheumatoid arthritis, atopic dermatitis, psoriasis, asthma and allergies, and inhibitors of such receptors are expected to be useful in the treatment of such diseases, and in the treatment of other inflammatory diseases or conditions such as inflammatory bowel disease, multiple sclerosis, solid organ transplant rejection and graft v. host disease.
  • This compound is described and claimed in United States Patent No. 6,720,325 , the disclosure of which is incorporated herein by reference.
  • the present application teaches a novel process of making a compound of formula I.
  • the compound of formula I is prepared from a compound of formula V: where X is selected from the group consisting of: p-methoxybenzyl (PMB), allyl, methoxymethyl, benzyloxymethyl, trityl, pivaloyloxymethyl, tetrahydranyl, benzyl, di(p-methoxyphenyl)methyl, triphenylmethyl, (p-methoxyphenyl)diphenylmethyl, and t-butyl carbamate (“t-Boc"); and Y is selected from the group consisting of: carbobenzyloxy (Cbz), CZ 3 CO (where Z is a halogen), 2-trimethylsilylethyl carbamate, 1-methyl-1-phenylethyl carbamate, t-butyl carbamate, cyclobutyl carbamate, 1-methylcyclobutyl carbamate, a
  • the inventive process comprises the sequential steps of:
  • the inventive process to make the compound of formula I has numerous advantages including it is economical and can be easily scaled-up.
  • Acyl means an H-C(O)-, alkyl-C(O)-, cycloalkyl-C(O)-, or aryl-C(O)- and the like. The bond to the parent moiety is through the carbonyl.
  • Alkyl means an aliphatic hydrocarbon group which may be straight or branched and comprising about 1 to about 20 carbon atoms in the chain. Preferred alkyl groups contain about 1 to about 12 carbon atoms in the chain. More preferred alkyl groups contain about 1 to about 6 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkyl chain. "Lower alkyl” means a group having about 1 to about 6 carbon atoms in the chain which may be straight or branched.
  • substituted alkyl means that the alkyl group may be substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, aryl, cycloalkyl, cyano, hydroxy, alkoxy, alkylthio, amino, -NH(alkyl), -NH(cycloalkyl), -N(alkyl) 2 , carboxy and -C(O)O-alkyl.
  • suitable alkyl groups include methyl, ethyl, n-propyl, isopropyl and t-butyl.
  • Alkylsulfonate means an alkyl-S(O 2 )-O- group in which the alkyl group is as previously described. Preferred groups are those in which the alkyl group is lower alkyl. The bond to the parent moiety is through the oxygen.
  • Aryl means an aromatic monocyclic or multicyclic ring system comprising about 6 to about 14 carbon atoms, preferably about 6 to about 10 carbon atoms.
  • the aryl group can be optionally substituted with one or more "ring system substituents" which may be the same or different, and are as defined herein.
  • suitable aryl groups include phenyl and naphthyl.
  • Cycloalkyl means a non-aromatic mono- or multicyclic ring system comprising about 3 to about 10 carbon atoms, preferably about 5 to about 10 carbon atoms. Preferred cycloalkyl rings contain about 5 to about 7 ring atoms.
  • Halide means fluoro, chloro, bromo or iodo.
  • Halogen means fluoro, chloro, bromo or iodo.
  • Heterocyclic means a non-aromatic saturated monocyclic or multicyclic ring system comprising about 3 to about 10 ring atoms, preferably about 4 to about 7 ring atoms, in which one or more of the atoms in the ring system is an element other than carbon, for Preparative Example nitrogen, oxygen or sulfur, alone or in combination. There are no adjacent oxygen and/or sulfur atoms present in the ring system.
  • Preferred heterocyclyls contain about 5 to about 6 ring atoms.
  • the prefix aza, oxa or thia before the heterocyclyl root name means that at least a nitrogen, oxygen or sulfur atom respectively is present as a ring atom.
  • Any -NH in a heterocyclyl ring may exist protected such as, for example, as an -N(Boc), -N(cbz), -N(Tos) group and the like; such protections are also considered part of this invention.
  • PMB means p-methoxybenzyl
  • Triflate means trifluoromethanesulfonyl.
  • the present invention discloses a novel, easy-to-use process for preparing the compound of formula I.
  • the process comprises:
  • X and Y are not the same moiety since X and Y are to be differentiated under the reaction conditions employed.
  • PMB p-methoxybenzyl
  • the preferred protecting group for Y is carbobenzyloxy (Cbz):
  • the deprotection in step (d) is performed using 2,3-dichoro-5,6-dicyano-1,4-benzoquinone or trifluoroacetic anhydride.
  • the deprotection is performed using trifluoroacetic anhydride.
  • the preferred W in step (e) is Cl.
  • step (f) is performed using strong acids such as sulfuric acid, hydrochloric acid, hydrobromic acid, methanesulfonic acid and the like.
  • the protection is accomplished using methanesulfonic acid.
  • the reaction in step (g) comprises (1) converting compound of formula VIII to a free base by use of a basic compound and (2) reacting free base with an agent containing a leaving group G and the compound of Formula VIIIa: where G is a leaving group preferably selected from the group consisting of CN, Z, OSO 2 R 2 , OCOCZ 3 and benzotriazolyl, with R 2 being an alkyl or aryl group and Z is a halogen.
  • G is a leaving group preferably selected from the group consisting of CN, Z, OSO 2 R 2 , OCOCZ 3 and benzotriazolyl, with R 2 being an alkyl or aryl group and Z is a halogen.
  • an agent containing a leaving group G refers to a compound that upon reaction as shown herein, leaves a moiety G described above on the compound being reacted.
  • G is a leaving group preferably selected from the group consisting of CN, Z, OSO 2 R 2 , OCOCZ 3 and benzotriazolyl
  • the compound (agent) contains in it as bonded moiety CN, Z, OSO 2 R 2 , OCOCZ 3 or benzotriazolyl, and then leaves the CN, Z, OSO 2 R 2 , OCOCZ 3 or benzotriazolyl upon being reacted with the compound of Formula VIII to form the compound of Formula IX as a result of said reaction.
  • the more preferred agent containing a leaving group is a cyanating agent and is selected from the group consisting of: HCN, acetone cyanohydrin; cyclohexanone cyanohydrin; a mixture of (C 2 H 5 )AlCN and Ti(OPr) 4 , a mixture of acetic acid, H 2 SO 4 ; NaHSO 4 , KHSO 3 or Na 2 S 2 O 5 and a cyanide source such as NaCN or KCN; trimethylsilylcyanide; glycolonitrile; mandelonitrile; glycinonitrile; acetone amino nitrile; and dimethylaminoacetonitrile.
  • the cyanating agent is acetone cyanohydrin.
  • the acetone cyanohydrin is used in about 1-5 molar equivalents with respect to the compound of formula VIII.
  • the compound of Formula VIIIa is used in about 1-4 molar equivalents with respect to the compound of formula VIII.
  • the basic compound in step (g) is selected from the group consisting of a metal hydroxide, oxide, carbonate and a bicarbonate, wherein the metal is selected from the group consisting of lithium, sodium, potassium, rubidium, cesium, beryllium, magnesium, calcium, strontium, barium, aluminum, indium, thallium, titanium, zirconium, cobalt, copper, silver, zinc, cadmium, mercury and cerium; a metal salt of a C 1 -C 12 alkanol, a C 3 -C 12 cycloalkanol, a (C 3 -C 8 cycloalkyl)C 1 -C 6 alkanol; ammonia, a C 1 -C 12 alkylamine, a di(C 1 -C 12 alkyl)amine, a C 3 -C 8 cycloalkylamine, a N-(C 3 -C 8 cycloalkyl)-N-(C 1 -C 12 alkyl)
  • a di(C 3 -C 8 cycloalkyl)amine a (C 3 -C 8 cycloalkyl)C 1 -C 6 alkylamine, a N-(C 3 -C 8 -cycloalkyl)C 1 -C 6 -alkyl-N-(C 1 -C 12 alkyl)amine, a N-(C 3 -C 8 cycloalkyl)C 1 -C 6 alkyl-N-(C 3 -C 8 cycloalkyl)amine, a di[(C 1 -C 6 cycloalkyl)C 1 -C 6 alkyl[amine; and a heterocyclic amine selected from the group consisting of imidazole, triazole, pyrrolidine, piperidine, heptamethyleneimine, morpholine, thiomorpholine and a 1-(C 1 -C 4 alkyl)piperazine.
  • the basic compound is selected from the group consisting of KOH, NaOH, Na 2 CO 3 , K 2 CO 3 , NaHCO 3 , KHCO 3 , tetramethylguanidine, DBU, diisopropylethylamine and mixtures thereof. More preferably, the basic compound is Na 2 CO 3 or K 2 CO 3 . Most preferably, the basic compound is K 2 CO 3 .
  • the Grignard reagent in step (h) is selected from the group consisting of MeMgCl, MeMgBr and MeMgl and is most preferably MeMgCl.
  • the MeMgCl is used in about 1-4 molar equivalents with respect to the compound of formula IX.
  • the solvent in step (h) is selected from the group consisting of toluene, xylene, chlorobenzene, or dichlorobenzene alone or in admixture with a solvent selected from the group consisting of a C 5 -C 12 alkyl ether, 1,2-dimethoxyethane, 1.2-diethoxyethane, diglyme, 1,4-dioxane and tetrahydrofuran.
  • the preferred solvent is a mixture of toluene and tetrahydrofuran.
  • the work-up in step (h) is treatment with an acid such as sulfuric acid, hydrochloric acid, phosphoric acid, and the like, in an aqueous phase and is preferably hydrochloric acid.
  • an acid such as sulfuric acid, hydrochloric acid, phosphoric acid, and the like
  • the application teaches a method for the preparation of a compound of formula V from a compound of formula IV: wherein the process comprises reacting the compound of formula IV with (i) benzotriazole, nitriles, halogens, alkylsulfonates or haloalkyl esters, preferably benzotriazole; (ii) 3-fluorophenylmagnesium bromide, and (ii) the compound: in a suitable solvent to yield a compound of formula V.
  • the solvent is selected from the group consisting of hydrocarbons, halogenated hydrocarbons, ethers, and mixtures thereof, and is preferably a mixture of toluene and tetrahydrofuran.
  • alkyl refers to a monovalent group derived from a straight or branched chain saturated hydrocarbon by the removal of a single atom having from 1 to 8 carbon atoms, preferably from 1 to 6.
  • aryl represents a carbocyclic group having from 6 to 14 carbon atoms and having at least one benzenoid ring, with all available substitutable aromatic carbon atoms of the carbocyclic group being intended as possible points of attachment.
  • Preferred aryl groups include phenyl, 1-naphthyl and 2-naphthyl, and especially phenyl.
  • halogen represents fluorine, chlorine, bromine and iodine.
  • the compound of formula I may be further converted to the CCR5 antagonist of formula X by suitable procedures known to those skilled in the art.
  • the products of the various steps in the reaction schemes described herein may be isolated and purified by conventional techniques such as, for example, filtration, recrystallization, solvent extraction, distillation, precipitation, sublimation and the like, well known to those skilled in the art.
  • the products may be analyzed and/or checked for purity by conventional methods well known to those skilled in the art such as, for example, thin layer chromatography, NMR, HPLC, melting point, mass spectral analysis, elemental analysis and the like.
  • Compound III is prepared from compound II and p-anisaldehyde via reductive amination.
  • Compound II 50 g, 318 mmol
  • p-Anisaldehyde 45.5g, 1.05 equiv
  • the mixture is stirred for about 16 hours at room temperature.
  • the reaction is quenched with the addition of water (150 mL), and THF is removed via vacuum distillation.
  • MTBE and water are added to the batch followed by pH adjustment to 1.5-2.5 with hydrochloric acid.
  • the batch is filtered to remove boric acid before splitting the layers.
  • the product containing aqueous layer is washed with MTBE. After splitting, fresh MTBE is charged to aqueous layer followed by pH adjustment to 9-11 with sodium hydroxide. After splitting, the aqueous layer is charged with MTBE, the mixture is filtered and the phases are separated.
  • the combined organic layers are concentrated and diluted with toluene.
  • the batch is concentrated under vacuum to a final volume of 150 mL. This solvent displacement provides III in about 90-95% yield as an approximately 50% solution in toluene.
  • the product solution is filtered to remove residual solids and is used directly in the next step.
  • Literature reference Abe, T.; Haga, T.; Negi, S.; Morita, Y.; Takayanagi, K.; Hamamura, K. Tetrahedron, 2001, 57, 2701 .
  • the modified Red-Al reagent is prepared according to the above literature reference: Red-Al solution (150 mL, 70wt% in toluene) is charged to a clean reaction vessel under nitrogen. MTBE (180 mL) is added to dilute the reagent and the batch is cooled to -25°C. Pyrrolidine (52 mL) is slowly charged to the batch maintaining the temperature below - 5°C. The batch is warmed to 25°C and agitated for 10 hours. A slurry of potassium t-butoxide (4.3 g) in THF (12 mL) is added and the mixture is agitated for 1 hour to give the modified Red-Al reagent.
  • the pH of combined bisulfite extracts is adjusted to 9-10 using potassium carbonate (approx. 120 g) in water (250 mL).
  • the precipitated bisulfite salt IVa is collected by filtration and washed with MTBE. A sample of the bisulfite salt was dried to give a white solid.
  • the wet bisulfite salt IVa is suspended in MTBE (300 mL) at 25°C and treated with 25% NaOH (250 mL) for 1 hour. After split, product containing organic layer is concentrated and the solvent is exchanged to toluene to a final volume of 300 mL. The solution of III in toluene is used directly in the next step.
  • Benzotriazole (57.0 g), toluene (1 L) and solution of A (105.5 g active) in toluene are charged to vessel equipped with a Dean-Stark collection apparatus under nitrogen.
  • a solution of IV (100.0 g active, 429 mmol) in toluene is charged keeping the batch temperature below 30°C.
  • the batch is heated to reflux (110 - 120°C) and agitated until water collection in the Dean-Stark trap is complete.
  • the batch is atmospherically concentrated and a sample is taken to check for reaction completion by NMR and batch KF.
  • the batch is further concentrated under vacuum to 300 mL.
  • Anhydrous THF (1800 mL) is added at 50-60°C and the batch is cooled to 15°C.
  • a solution of 3-fluorophenylmagnesium bromide in THF (643 mL of 1.0 M solution) is slowly charged to the batch keeping the batch temperature below 25°C.
  • the batch is quenched at 0°C by adding a solution of sodium citrate in water (100 mL, 22 wt%) and the organic layer is concentrated to 800 mL by atmospheric distillation.
  • the batch is cooled to 25 °C and MTBE (800 mL) is added followed by a solution of sodium citrate in water (500 mL, 22 wt%) are added.
  • the batch is warmed up to 35 °C and agitated for 15 min.
  • the aqueous layer is extracted with fresh MTBE (500 mL).
  • a solution of V (109 g, 199 mmol) is cooled to 0 °C and triethylamine (56 mL) is added. Trifluoroacetic anhydride (56 mL) is added slowly to the batch keeping the temperature below 10°C. The batch is warmed to 20°C and agitated for 1 hour. A sample is taken to check for reaction completion by HPLC. Batch is cooled to 0°C and water (300 mL) is charged keeping the temperature below 10°C. Batch is agitated for 30 min, settled, and aqueous layer is split to waste. The organic layer is a solution of compound Va .
  • a warm solution of V (80 g active, 147 mmol) is diluted with EtOH (1000 mL) and concentrated atmospherically to a final volume of 700 mL.
  • Batch is cooled to 25°C and aqueous solution of NaOH (170 mL, 50 wt%) is charged keeping the batch temperature below 40°C.
  • the batch is heated to reflux and agitated at reflux for about 6 hours until the conversion is complete by HPLC.
  • the batch is cooled to 25°C and concentrated under vacuum to a volume of about 300 mL. Water (600 mL) and MTBE (500 mL) are added to the batch, temperature is adjusted to 30-40°C.
  • the aqueous layer is extracted with fresh MTBE (200 mL), and organic layers are combined.
  • the product is back-extracted with dilute hydrochloric acid at pH ⁇ 5-6.
  • the aqueous layer is washed with fresh MTBE, diluted with MTBE (500 mL), and the batch pH is adjusted to 12-14 with sodium hydroxide.
  • Aqueous layer is split, extracted with fresh MTBE (500 mL).
  • the combined organic layers are washed with water and concentrated by atmospheric distillation to 400 mL volume and cooled to 40°C. Isopropyl alcohol is charged (1600 mL) and the batch is concentrated by atmospheric distillation to 1200 mL volume.
  • the batch is settled for at least 1 hour and then the product containing aqueous layer split.
  • THF is added to the aqueous layer and the batch is cooled to 0 °C.
  • Batch pH is carefully adjusted to 8-10 range using 50 wt% sodium hydroxide keeping the temperature below 30 °C.
  • the aqueous layer is split to waste, and organic layer is concentrated solvent-exchanged to isopropyl alcohol.
  • the batch is passed twice through CUNO ® cartridges containing DARCO ® -G60.
  • the batch is heated to 75°C and 48% hydrobromic acid solution (98 g) is added slowly.
  • the batch is heated to reflux (80-85°C) and agitated for 3-5 hours until the start of product crystallization.
  • the filtrate is atmospherically concentrated to 400 mL and heptane (150 mL) containing compound IX seeds is added at reflux. After heated at reflux for 1 hour, additional heptane (150 mL) is added at reflux. The resulting slurry is heated at reflux for 1 hour and cooled over 1 hour to room temperature. After stirring at room temperature for 1 hour, the slurry is filtered and washed with 1:1 ethyl acetate/heptane (200 mL). The wet cake is dried at 45°C under vacuum overnight to give a white solid (96 g, 84% yield). m.p.: 185°C by DSC.
  • the organic layer was washed with 1.5M aqueous HCl (442 ml).
  • the aqueous acidic layer was digested at 35-45°C for 4 hours and then cooled to 15-25°C.
  • the aqueous layer was neutralized with 25% aqueous NaOH (119 mL) and then extracted into isopropyl acetate (1250 mL).
  • the organic layer was washed with water (500 mL) and then evaporated under vacuum to give a foam. The yield was 96%.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP06717461A 2005-01-06 2006-01-05 Synthesis of ccr5 receptor antagonists Active EP1833817B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64190005P 2005-01-06 2005-01-06
PCT/US2006/000262 WO2006074270A2 (en) 2005-01-06 2006-01-05 Synthesis of ccr5 receptor antagonists

Publications (2)

Publication Number Publication Date
EP1833817A2 EP1833817A2 (en) 2007-09-19
EP1833817B1 true EP1833817B1 (en) 2010-10-13

Family

ID=36571985

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06717461A Active EP1833817B1 (en) 2005-01-06 2006-01-05 Synthesis of ccr5 receptor antagonists

Country Status (13)

Country Link
US (2) US7728135B2 (zh)
EP (1) EP1833817B1 (zh)
JP (1) JP2008526863A (zh)
CN (1) CN101137646A (zh)
AR (1) AR054422A1 (zh)
AT (1) ATE484500T1 (zh)
CA (1) CA2594114A1 (zh)
DE (1) DE602006017507D1 (zh)
HK (1) HK1102303A1 (zh)
MX (1) MX2007008280A (zh)
SG (1) SG158861A1 (zh)
WO (1) WO2006074270A2 (zh)
ZA (1) ZA200705524B (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20094680B (en) 2004-04-13 2009-05-10 Incyte Corp Piperazinylpiperidine derivatives as chemokine receptor antagonists
CA2673233A1 (en) * 2006-12-22 2008-07-03 Schering Corporation Process for preparing ccr-5 receptor antagonists utilizing 4-substituted 1-cyclopropane-sulfonyl-piperidinyl compounds
EP2720754B1 (en) 2011-06-19 2016-10-19 New York University Leukotoxin e/d as a new anti-inflammatory agent and microbicide
CN103804445B (zh) * 2013-12-30 2016-01-13 广州自远生物科技有限公司 一种改进的乙酰异戊酰泰乐菌素的制备方法
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
DE60236218D1 (de) * 2001-03-29 2010-06-10 Schering Corp CCR5 Antagonisten verwendbar für die Behandlung von Aids

Also Published As

Publication number Publication date
AR054422A1 (es) 2007-06-27
EP1833817A2 (en) 2007-09-19
JP2008526863A (ja) 2008-07-24
WO2006074270A2 (en) 2006-07-13
HK1102303A1 (en) 2007-11-16
ZA200705524B (en) 2008-09-25
DE602006017507D1 (de) 2010-11-25
ATE484500T1 (de) 2010-10-15
CN101137646A (zh) 2008-03-05
WO2006074270A3 (en) 2007-10-04
SG158861A1 (en) 2010-02-26
CA2594114A1 (en) 2006-07-13
US20060258863A1 (en) 2006-11-16
MX2007008280A (es) 2007-09-07
US20100036125A1 (en) 2010-02-11
US7728135B2 (en) 2010-06-01

Similar Documents

Publication Publication Date Title
EP1926705B1 (en) Process for preparing valsartan
US8008479B2 (en) Organic compounds
DK2593429T3 (en) A process for preparing a biphenyl-2-ylcarbamic acid
JPH0757748B2 (ja) ３−アミノピペリジン誘導体及び関連する窒素含有複素環化合物
EP1833817B1 (en) Synthesis of ccr5 receptor antagonists
EP2240441B1 (en) Process for the preparation of 6-substituted-1-(2h)-isoquinolinones
WO2023104920A1 (en) Crystalline acetone solvate of revefenacin
JP6152088B2 (ja) アルガトロバン一水和物合成のためのプロセス中間体の製造方法
AU2008288430A1 (en) Novel preparation process
JP2010254692A (ja) パリペリドンの精製方法
US7473778B2 (en) 3-(4-piperidinyl)-2,3,4,5-tetrahydro-1,3-benzodiazepin-2(1H)-one
JP2020070296A (ja) リナグリプチンの製造法
KR101628946B1 (ko) 실로도신의 개선된 제조방법
EP3365327B1 (en) Process for the preparation of fexofenadine and of intermediates used therein
EP2616464B1 (en) Improved process for the preparation of a precursor of sufentanil base
KR101009404B1 (ko) (에스)-엔-(1-카르복시-2-메틸-프로-1-필)-엔-펜타노일-엔-[2'-(1에이취-테트라졸-5-일)비페닐-4-일-메틸]아민화합물의 고순도 제조방법
KR20200088570A (ko) 피마살탄 및 그의 제조 중간체의 제조방법
US9512077B2 (en) Process for the preparation of methylphenidate hydrochloride and its intermediates thereof
WO2008079284A1 (en) Process for preparing ccr-5 receptor antagonists utilizing 4-substituted 1-cyclopropane-sulfonyl-piperidinyl compounds
US20040181070A1 (en) Process and intermediates for the preparation of 4-aryl piperidines
JP2010526126A (ja) バルサルタンの製造方法
JPH10147593A (ja) ３−アミノステロイド誘導体の製造方法
KR20110089671A (ko) 발사르탄의 제조 방법 및 이에 사용되는 신규 중간체

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070713

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1102303

Country of ref document: HK

R17D Deferred search report published (corrected)

Effective date: 20071004

RIN1 Information on inventor provided before grant (corrected)

Inventor name: WU, WENXUE

Inventor name: SHIH, XIONGWEI

Inventor name: ZHU, MAN

Inventor name: DAHANUKAR, VILAS

Inventor name: ZAVIALOV, ILIA, A.

Inventor name: TRAN, LOC, THANH

Inventor name: LEONG, WILLIAM

Inventor name: ZHAO, SHANNON

Inventor name: ORR, CECILIA

Inventor name: LEE, HONG-CHANG

Inventor name: LIU, YI

Inventor name: NGUYEN, HOA, N.

Inventor name: LIANG, FENG

Inventor name: D'SA, BOSCO

17Q First examination report despatched

Effective date: 20081006

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LEE, HONG-CHANG

Inventor name: LEONG, WILLIAM

Inventor name: WU, WENXUE

Inventor name: ZAVIALOV, ILIA, A.

Inventor name: TRAN, LOC, THANH

Inventor name: SHIH, XIONGWEI

Inventor name: LIU, YI

Inventor name: NGUYEN, HOA, N.

Inventor name: ZHAO, SHANNON

Inventor name: LIANG, FENG

Inventor name: ZHU, MAN

Inventor name: PROIETTI, CECILIA

Inventor name: DAHANUKAR, VILAS

Inventor name: D'SA, BOSCO

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REF Corresponds to:

Ref document number: 602006017507

Country of ref document: DE

Date of ref document: 20101125

Kind code of ref document: P

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20101028

Year of fee payment: 6

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20101013

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101013

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101013

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101013

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110214

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101013

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101013

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101013

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110113

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110213

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101013

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110114

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101013

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110124

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101013

REG Reference to a national code

Ref country code: NL

Ref legal event code: V1

Effective date: 20110801

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101013

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101013

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101013

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110131

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101013

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

26N No opposition filed

Effective date: 20110714

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20110113

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20110930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110131

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110131

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110131

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1102303

Country of ref document: HK

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602006017507

Country of ref document: DE

Effective date: 20110714

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110113

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602006017507

Country of ref document: DE

Effective date: 20110802

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101013

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110801

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120105

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101013

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110105

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110802

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101013

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101013